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ABSTRACT Inﬂuenza A and B viruses and respiratory syncytial virus (RSV) are three
common viruses implicated in seasonal respiratory tract infections and are a major
cause of morbidity and mortality in adults and children worldwide. In recent years,
an increasing number of commercial molecular tests have become available to diag-
nose respiratory viral infections. The Luminex Aries Flu A/B & RSV assay is a fully au-
tomated sample-to-answer molecular diagnostic assay for the detection of inﬂuenza
A, inﬂuenza B, and RSV. The clinical performance of the Aries Flu A/B & RSV assay
was prospectively evaluated in comparison to that of the Luminex xTAG respiratory
viral panel (RVP) at four North American clinical institutions over a 2-year period. Of
the 2,479 eligible nasopharyngeal swab specimens included in the prospective study,
2,371 gave concordant results between the assays. One hundred eight specimens
generated results that were discordant with those from the xTAG RVP and were fur-
ther analyzed by bidirectional sequencing. Final clinical sensitivity values of the Aries
Flu A/B & RSV assay were 98.1% for inﬂuenza A virus, 98.0% for inﬂuenza B virus,
and 97.7% for RSV. Final clinical speciﬁcities for all three pathogens ranged from 98.6%
to 99.8%. Due to the low prevalence of inﬂuenza B, an additional 40 banked inﬂuenza
B-positive specimens were tested at the participating clinical laboratories and were
all accurately detected by the Aries Flu A/B & RSV assay. This study demonstrates
that the Aries Flu A/B & RSV assay is a suitable method for rapid and accurate iden-
tiﬁcation of these causative pathogens in respiratory infections.
KEYWORDS PCR, inﬂuenza, rapid tests, respiratory syncytial virus
Respiratory infections are a signiﬁcant cause of morbidity, mortality, hospitalization,and health care costs worldwide (1). These infections cause acute local and
systemic illnesses that range in severity and have the potential to cause severe disease,
especially in the young and elderly. The vast majority (90%) of these are viral in nature
(2, 3), although as many as 60% of patients are ineffectively treated with antibiotics for
these viral infections (4).
The economic impact of overprescribing antibiotics is 2-fold, including the initial
costly misuse of the antibiotics plus the ultimate cost of treating antibiotic-resistant
infections (ARI) later on. Such occurrence of ARI has been estimated to cost more than
$20,000 per infected patient (5). The clinical impact of overprescribing antibiotics
includes the increased spread of viral infections, increased bacterial drug resistance,
and increased cost (6). Knowing whether a respiratory infection is viral or bacterial
allows for more effective patient isolation and infection control (1).
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Respiratory viruses such as inﬂuenza virus and respiratory syncytial virus (RSV) are
the most common cause of acute illness and physician visits in the United States (7).
The frequency of respiratory viral infections is highest in children under 4 years of age.
School-age children average 5 to 8 respiratory virus infections per year, and adults
average 2 to 4 infections per year (8, 9). In the United States, an estimated 200,000
people are hospitalized annually due to inﬂuenza alone, with more than 36,000, typically
the elderly and immunocompromised, dying from the disease each year (10).
Traditional laboratory tests, such as culture, serology, and direct immunoﬂuores-
cence, have been used to identify the infectious pathogens. However, the slow results
from culture and the poor reliability of rapid immunoassay-based respiratory tests
present challenges to clinicians and hospitals (1). Molecular diagnostic tests such as PCR
methods offer high sensitivity, speed, and cost advantages over traditional methods,
such as culture or direct immunoﬂuorescence (DFA), and have been the focus of clinical
laboratories for more than a decade. Rapid and early diagnosis of the causative
pathogen in respiratory illness aids in patient diagnosis, treatment management, and
the avoidance of overprescribing antibiotics.
The Aries Flu A/B & RSV assay (Luminex Corporation) is a real-time PCR-based in vitro
diagnostic test for the identiﬁcation of inﬂuenza A virus, inﬂuenza B virus, and respi-
ratory syncytial virus (RSV) in nasopharyngeal swabs (NPS) from patients with suspected
respiratory tract infections. The assay is used with the Aries instrument, a clinical
multiplex test system that automates nucleic acid preparation from a clinical sample,
performs real-time PCR detection, and reports multiple test results from the assay. The
NPS specimen is introduced into the Aries Flu A/B & RSV assay cassette by pipetting,
and the cassette is placed into an Aries system module via a cassette magazine. Within
the assay cassette, the specimen is lysed and the nucleic acids are extracted along with
the sample processing control (SPC) present in the cassette. The extracted nucleic acids
are transferred to lyophilized PCR reagents contained within the PCR tube attached to
the cassette.
The assay uses target-speciﬁc ﬂuorescently labeled primer pairs to amplify nucleic
acid sequences from inﬂuenza A/B virus and RSV found in the sample, in addition
to amplifying assay internal control sequences. The Aries assay chemistry is based
on an expanded genetic alphabet technology, using the synthetic DNA base pair
2=-deoxy-5-methyl-isocytidine (iC) · 2=-deoxyisoguanosine (iG). The isobases (iC and
iG) pair speciﬁcally with each other and not with natural nucleotides and are
efﬁciently incorporated during PCR (11, 12). During PCR ampliﬁcation, a quencher-
modiﬁed iGTP is incorporated by the polymerase opposite to an iC and a ﬂuorophore
reporter attached to the PCR primer. If the target is present and is ampliﬁed, the assay
ﬂuorescence decreases with every cycle as the ampliﬁcation product accumulates. The
decrease in assay ﬂuorescence is monitored in real time on the Aries instrument.
Reported herein are the results of a multicenter clinical performance study that
evaluated the Aries Flu A/B & RSV assay over a 2-year period on 2,479 pediatric and
adult subjects with suspected respiratory infections presenting at four different North
American clinical institutions. The clinical performance of the Aries Flu A/B & RSV assay
for detecting inﬂuenza A virus, inﬂuenza B virus, and RSV was determined in compar-
ison to that of the FDA-approved xTAG respiratory viral panel (RVP).
RESULTS
A total of 2,504 NPS specimens from subjects suspected of having respiratory tract
infections were collected in the prospective study. Twenty-ﬁve specimens were ex-
cluded based on inclusion/exclusion criterion violation or protocol deviation, leaving a
total of 2,479 eligible unique specimens for subsequent data analysis. Of these, 1,017
were collected from January to March 2015, while the remaining 1,462 specimens were
obtained between November 2015 and February 2016.
Table 1 summarizes the general demographic information from the subjects that
were included in the data analysis. Among the 2,479 specimens included in the analysis,
47.1% were from male patients (n  1,168) and 52.9% (n  1,311) were from female
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patients. Most of the specimens were collected from individuals who either were
hospitalized or presented to the institutions’ emergency departments (52.4% and
28.9%, respectively). Outpatients represented 18.7% of the study population. A total of
1,577 (63.6%) subjects were adults 21 years of age or older, while the remaining 902
(36.4%) subjects were pediatric patients 21 years of age.
Clinical runs using the Aries Flu A/B & RSV assay were conducted between Decem-
ber and March 2016 on specimens that were either stored frozen at 80°C (n  1,316
[53.1%]) or kept refrigerated at 4°C to 8°C (n  1,163 [46.9%]) prior to testing. The vast
majority of the frozen samples (77.3% [n  1,017]) was kept stored for 3 to 12 months,
while 23.6% of samples were collected 1 to 3 months before testing with the Aries Flu
A/B & RSV assay. A difference in sensitivity with regard to the age of frozen specimens
could not be detected. Similarly, when comparing storage conditions, no signiﬁcant
difference between the frozen and refrigerated sample results could be seen (data not
shown).
Valid Aries Flu A/B & RSV assay results (i.e., positive or negative) were obtained on
the ﬁrst attempt from 2,458 specimens (2,458/2,479 [99.2%]). Invalid assay results were
reported from 21 specimens (21/2,479 [0.8%]). All 21 specimens in question generated
valid Aries results upon repeat testing. The positive rate of the Aries Flu A/B & RSV assay
for each viral target is summarized in Table 2. Among the 2,479 specimens tested,
13.5% were positive for inﬂuenza A virus (n  334) and 12.3% were positive for RSV
(n  306). The prevalence of inﬂuenza B virus in the study population was low (2.4%
[n  59]). The majority of RSV infections (n  194 [63.4%]) were reported in pediatric
subjects 21 years of age, while most inﬂuenza A cases (n  247 [73.9%]) were from
adults 21 years of age or older. Inﬂuenza B infections were evenly distributed between
age groups (49.1% in pediatric cases versus 50.9% in adult cases).
Table 3 summarizes the performance characteristics of the Aries Flu A/B & RSV assay
using the xTAG respiratory viral panel (RVP) as the comparator. Clinical sensitivity (or
positive percent agreement [PPA]) of the Aries Flu A/B & RSV assay was 95.8% for
inﬂuenza A virus (299/312; 95% conﬁdence interval [CI], 93.0% to 97.8%), 93.8% for
inﬂuenza B virus (45/48; 95% CI, 82.8% to 98.7%), and 97.1% for RSV (270/278; 95% CI,
TABLE 1 General demographic details of the study population
Characteristic
No. (%) at site (location):
1 (NY) 2 (TX) 3 (MO) 4 (ON) All sites
Sex
Male 375 (46.2) 134 (41.0) 200 (51.7) 459 (48.1) 1,168 (47.1)
Female 436 (53.8) 193 (59.0) 187 (48.3) 495 (51.9) 1311 (52.9)
Total 811 327 387 954 2479
Age (years)
1 37 (4.6) 32 (9.8) 102 (26.4) 263 (27.6) 434 (17.5)
1–5 29 (3.6) 29 (8.9) 62 (16.0) 103 (10.8) 223 (9.0)
5–21 29 (3.6) 49 (15.0) 64 (16.5) 103 (10.8) 245 (9.9)
21–65 316 (39.0) 131 (40.1) 124 (32.0) 274 (28.7) 845 (34.1)
65 400 (49.3) 86 (26.3) 35 (9.0) 211 (22.1) 732 (29.5)
Total 811 327 387 954 2,479
Subject status or placement
Outpatient 147 (18.1) 167 (51.1) 85 (22.0) 64 (6.7) 463 (18.7)
Hospitalized 484 (59.7) 111 (33.9) 158 (40.8) 546 (57.2) 1,299 (52.4)
Emergency department 180 (22.2) 48 (14.7) 144 (37.2) 344 (36.1) 716 (28.9)
Long-term care facility 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.0)
Total 811 327 387 954 2479
Immune status
Immunocompromiseda 177 (21.8) 87 (26.6) 0 (0.0) 84 (8.8) 348 (14.0)
Immunocompetent 628 (77.4) 239 (73.1) 0 (0.0) 870 (91.2) 1,737 (70.1)
Not determined 6 (0.7) 1 (0.3) 387 (100.0) 0 (0.0) 394 (15.9)
Total 811 327 387 954 2,479
aDeﬁned as patients with HIV or AIDS, transplant, oncology, or diabetes.
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94.4% to 98.7%). The clinical speciﬁcity (or negative percent agreement [NPA]) of the
Aries Flu A/B & RSV assay for all three respiratory pathogens ranged from 98.4% to
99.4%. Clinical sensitivity values by testing site ranged from 93.8% to 100% for inﬂuenza
A virus, from 85.7% to 100% for inﬂuenza B virus, and from 95.7% to 100% for RSV.
Clinical speciﬁcity values by testing site ranged from 97.4% to 99.5% for all targets. No
signiﬁcant differences in assay sensitivity and speciﬁcity were reported in different age
groups (0 to 1, 1 to 5, 5 to 21, 21 to 65, and 65 years of age) (data not shown).
Similarly, no substantial differences in sensitivity and speciﬁcity values for all three
targets could be noticed between the two seasons of testing, namely, 2014 to 2015 and
2015 to 2016.
The positive predictive value (PPV) of the Aries Flu A/B & RSV assay was 89.8% for
inﬂuenza A virus (299/399; 95% CI, 86.0% to 92.8%), 76.3% for inﬂuenza B virus (45/59;
95% CI, 63.4% to 86.4%), and 88.2% for RSV (270/306; 95% CI, 84.1% to 91.6%). The
negative predictive values (NPVs) of the Aries Flu A/B & RSV assay for all three
respiratory pathogens ranged from 99.4% to 99.9%. It is important to note that
predictive values should not be considered intrinsic to any test, as they vary depending
on the disease prevalence. Although the PPV of the Aries assay for inﬂuenza B virus was
lower than those for inﬂuenza A virus and RSV, the prevalence of this virus (1.9%) was
also observed to be lower in the study population than for inﬂuenza A virus (12.6%) and
RSV (11.2%). This had a signiﬁcant impact on PPV despite the fact that the false
positivity rate of the assay for inﬂuenza B virus was only 0.6% in this evaluation
(14/2,479).
Twenty-four specimens were identiﬁed as positive by the comparator method but
negative by the Aries Flu A/B & RSV assay (i.e., false negative). Of these, 10 specimens
(41.7%) were conﬁrmed as negative by bidirectional sequencing analysis. These included 7
for inﬂuenza A virus, 2 for inﬂuenza B virus, and 1 for RSV. There were also 84 specimens
that were identiﬁed as negative by the reference method but positive by the Aries Flu A/B
& RSV assay (i.e., false positive). Of these, 39 specimens (46.2%) were conﬁrmed as positive
by sequencing analysis. These included 4 for inﬂuenza A virus, 3 for inﬂuenza B virus, and
32 for RSV.
Because the prevalence of inﬂuenza B virus was lower than those for inﬂuenza A virus
and RSV in the study population, the prospective sample set was supplemented with
archived specimens. A total of 40 unique preselected specimens positive for inﬂuenza B
virus were included in this supplemental evaluation. The specimens were tested in a blind










(n  845) >65 (n  732)
n % n % n % n % n % n %
Inﬂuenza A 334 13.5 17 3.9 30 13.5 40 16.3 151 17.9 96 13.1
Inﬂuenza B 59 2.4 4 0.9 5 2.2 20 8.2 19 2.2 11 1.5
RSV 306 12.3 133 30.6 47 21.1 14 5.7 39 4.6 73 10.0
Total 699 28.2 154 35.5 82 36.8 74 30.2 209 24.7 180 24.6
TABLE 3 Aries Flu A/B & RSV assay clinical performance summary in comparison to xTAG RVP assaya
Virus
Sensitivity (PPA [%]) Speciﬁcity (NPA [%]) Positive predictive value (%) Negative predictive value (%)
TP/(TP  FN) 95% CI TN/(TN  FP) 95% CI TP/(TP  FP) 95% CI TN/(TN  FN) 95% CI
Inﬂuenza Ab 95.8 (299/312) 93.0–97.8 98.4 (2,131/2,165) 97.8–98.9 89.8 (299/333) 86.0–92.8 99.4 (2,131/2,144) 99.0–99.7
Inﬂuenza B 93.8 (45/48) 82.8–98.7 99.4 (2,417/2,431) 99.0–99.7 76.3 (45/59) 63.4–86.4 99.9 (2,417/2,420) 99.6–99.9
RSV 97.1 (270/278) 94.4–98.7 98.4 (2,165/2,201) 97.7–98.9 88.2 (270/306) 84.1–91.6 99.6 (2,165/2,173) 99.3–99.8
aFN, false negative; FP, false positive; NPA, negative percent agreement; PPA, positive percent agreement; TN, true negative; TP, true positive.
bTwo specimens yielded invalid results for inﬂuenza A virus upon repeat xTAG RVP testing; both specimens were excluded from the assay performance calculations for this
virus.
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manner by the prospective study sites, and all were accurately detected by the Aries Flu A/B
& RSV assay (100%; 95% CI, 91.2% to 100%). When the results from these banked specimens
were combined with those from the prospective study, the detection rate of the Aries Flu
A/B & RSV assay for inﬂuenza B virus was 96.6% (85/88; 95% CI, 90.4% to 99.3%).
DISCUSSION
A rapid detection of viral pathogens causing a respiratory infection provides phy-
sicians a number of advantages in treating patients and managing outbreaks. In
addition to conﬁrming an infection’s viral basis and avoiding unnecessary antibiotics,
differential diagnosis of respiratory infections enables the isolation of hospital patients,
a reduction in the length of stay for minor infections, better control of outbreaks and
hospital transmission rates, and more cost-effective clinical outcomes (13, 14).
Traditional laboratory tests have limitations in the hospital setting, including a slow
time-to-result, poor assay performance, and high cost (1). Without rapid test results,
hospitalized patients either are not immediately isolated or are unnecessarily isolated
as a precaution, potentially creating inefﬁciencies and increased health care costs. A
poor sensitivity or speciﬁcity of an assay results in either inaccurate diagnoses or a lack
of conﬁdence in results. High assay costs make certain laboratory tests unfeasible and
shift the ﬁnancial burden to other aspects of clinical care, such as the decision to risk
a potential outbreak or to isolate patients merely as a precaution (15).
The advent of rapid molecular diagnostic tests for respiratory viruses allows clini-
cians to gain diagnostic insight early enough in treatment to immediately and effec-
tively impact clinical outcomes. However, such tests are only as effective as their proven
assay performance, providing conﬁdence and reliability for making the best possible
clinical care decisions. This multicenter clinical study demonstrated robust performance
of the Aries Flu A/B & RSV assay in subjects suspected of having respiratory tract
infections. The primary metrics addressed by this study are the clinical sensitivity and
speciﬁcity compared with those from existing molecular diagnostics for these patho-
gens. Other assay performance characteristics such as sample-to-answer time, ease of
use, and a reduction of errors were evaluated in terms of their impact on the usage of
the assay in the clinical setting.
The Aries system is a standalone sample-to-answer platform that does not require
additional equipment or computing power, minimizing the system’s footprint on the
laboratory bench. The system is capable of running cassette-based assays, including
both in vitro diagnostic (IVD) assays and user-deﬁned protocols. With onboard nucleic
acid extraction, internal controls, and barcode scanning, the instrument is designed to
minimize laboratory errors. The Flu A/B & RSV assay requires less than 10 min of
hands-on time, and results are available in approximately 2 h of run time for up to 12
samples per instrument, allowing assay results for all 3 pathogens to be reported for up
to 48 patient samples per 8-hour shift.
Reliability is an essential component when choosing the right assay for any clinical
setting. Unwanted repeat runs due to invalid results not only disrupt the laboratory
workﬂow but can also lead to extended turnaround times or even cancellation of
testing if insufﬁcient sample material is available for reruns. This is especially important
during seasonally driven high volumes and for decision making for triaging. The Aries
Flu A/B & RSV assay demonstrated a remarkably low value of 0.8% (21/2,479) of invalid
results. All of those 21 results needed to be repeated, but provided reliable results upon
repeat. Similar or inferior reliability data are seen with comparable assays; GenMark
Diagnostics eSensor RVP showed a 1.5% invalid rate, the Verigene RV Nanosphere
showed 9.7%, FilmArray RP (BioFire Diagnostics) showed 3% and 1%, and Prodesse Pro
Flu showed 5.7% (16–18). xTAG RVP (Luminex) performed with a 1.1% invalid rate in
this study and 2% elsewhere (19). Even the point-of-care approved assay Alere i showed
invalid rates of 4.6% and 5.1% in two studies, with the inability of reruns due to an
insufﬁcient quantity of specimen (20, 21).
Following discordant analysis and resolution, the performance of the Aries Flu A/B
& RSV assay ranged from 97.7 to 98.1% sensitivity and 98.6 to 99.8% speciﬁcity for all
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three pathogens, which is comparable to other U.S. FDA-cleared molecular respiratory
viral panels as reported in the scientiﬁc literature. For example, the study by Popowitch
et al. compared four commercially available molecular tests: FilmArray RP (BioFire
Diagnostics), eSensor RVP (GenMark Dx), xTAG RVP, and xTAG RVP FAST (Luminex
Molecular Diagnostics) (22). Clinical sensitivities for each test evaluated varied between
86.2% to 100% for inﬂuenza A virus, 45.5% to 100% for inﬂuenza B virus, and 86.4% to
100% for RSV. Speciﬁcity values were also reported to be high for all assays, at 99.2 to
99.9% overall. Recently, Voermans et al. compared the performance of the Aries Flu A/B
& RSV assay (RUO) to that of laboratory-developed reverse transcriptase PCR (RT-PCR)
assays (LDA), immunochromatographic assays, and a direct ﬂuorescent antibody. Clin-
ical sensitivities were 93.3 to 98.6% and clinical speciﬁcities were 100% compared with
those of LDA (23).
Limitations with this study include the chosen time for specimen collection that led
to the inferior amount of inﬂuenza B specimens, as they had just begun to appear in
each season and subsequently demanded a further collection process. Furthermore,
due to the inability to deﬁnitively identify inﬂuenza A H1N1 pdm09 strains by both
assays, namely, the Aries Flu A/B & RSV and the xTAG RVP, deﬁnitive conclusions about
the speciﬁc performance in the identiﬁcation of different inﬂuenza A strains that are
predominant during the seasons of testing cannot be drawn.
In conclusion, the Aries system and the Aries Flu A/B & RSV assay provide a rapid
reliable diagnostic tool for hospitals and clinical labs needing to identify viral patho-
gens earlier in the treatment continuum. The integrated sample-to-answer process
enables clinicians to make conﬁdent decisions about patient isolation, care, and
treatment that could potentially improve clinical outcomes and reduce health care
costs.
MATERIALS AND METHODS
Institutional and ethics reviews. The present study was conducted under institutional review board
(IRB) or research ethics board (REB) approval at all participating sites.
Prospective specimen collection, processing, and testing. Specimens included in this clinical
study included leftover nasopharyngeal swabs (NPS) prospectively collected during the 2014 to 2015 and
2015 to 2016 inﬂuenza seasons. Clinical specimens were collected from pediatric or adult patients
suspected of having respiratory tract infections who presented at four geographically diverse clinical
sites located in North America. Clinical sites were located in the eastern United States (Northwell Health
Laboratories, Lake Success, NY), central United States (Department of Pediatrics, Washington University,
St. Louis, MO), southwestern United States (Baylor Scott and White Health, College of Medicine, Temple,
TX), and Canada (Department of Pathology and Molecular Medicine, St. Joseph’s Healthcare, Hamilton,
Ontario, Canada). Respiratory sample collection was performed with each institution’s standardized NPS
collection kit and in accordance with their individual procedures. All clinical specimens were submitted
fresh to the institutions’ clinical laboratories and were processed as per their standard procedures and
as ordered by the referring physician. Specimens that were not properly collected, labeled, transported,
stored, or received timely and in good condition were excluded from the study.
Upon receipt, any leftover specimen that met these study inclusion/exclusion criteria was provided
in a blind manner to an individual at the site who was not directly involved in the study. Each eligible
specimen was then divided into multiple aliquots. One aliquot of the specimen was kept at the
clinical sites for Aries Flu A/B & RSV assay testing. Another aliquot of the specimen was shipped to
a centralized testing facility (Luminex Molecular Diagnostic, Toronto, Ontario, Canada) for compar-
ator xTAG RVP testing. Two additional specimen aliquots were generated and stored frozen at 80°C
for either repeat testing or discordance analysis.
Banked specimen collection and testing. Banked specimens were stored frozen at 80°C over a
period of 12 months prior to testing. Due to the lower prevalence of inﬂuenza B virus observed in the
prospective study, the sample set was supplemented with banked (preselected) inﬂuenza B-positive
specimens derived from both seasons, namely, 2014 to 2015 and 2015 to 2016. These specimens were
collected at a single clinical laboratory (collection site) located in Canada (Department of Pathology and
Molecular Medicine, St. Joseph’s Healthcare, Hamilton, Ontario, Canada). The presence of the expected
pathogen (inﬂuenza B virus) in each of the preselected specimens was conﬁrmed by xTAG RVP testing.
To minimize bias, preselected positive specimens (n  40) were distributed and tested along with an
equal number of unique negative specimens in a randomized double-blind fashion at the four testing
sites that were involved in the prospective study. Both positive and negative results were included in the
ﬁnal analysis.
Comparator testing with the xTAG RVP assay. An aliquot of each specimen was extracted using
the NucliSENS easyMAG method (bioMérieux, Inc.), and the total nucleic acid isolates were tested by the
xTAG RVP assay (Luminex Molecular Diagnostics, Toronto, Ontario, Canada) at a centralized testing
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facility. xTAG RVP testing was performed by trained personnel in accordance with the manufacturer’s
instructions provided in the kit package insert and within sample stability claims.
Aries Flu A/B & RSV assay testing. All specimens were assessed by the Aries Flu A/B & RSV assay
(Luminex Corporation, Austin, TX) by one or two trained operators at each of the clinical sites. These
operators were blind to the routine clinical results to minimize potential bias. Assay runs and allowable
reruns were performed in accordance with the manufacturer’s instructions. Brieﬂy, assay cassettes were
removed from the pouch and capped and the foil seal was removed. Sample tubes and assay cassettes
were placed in the Sample Prep tray. The samples were vortexed brieﬂy and 200 l from each was
pipetted into the assay cassettes. The cassette caps were closed and the loaded cassettes were placed
into the cassette magazine. The loaded magazine was inserted into one of two modules in the Aries
instrument and the run was started. In the ﬁrst phase of the prospective study (2014 to 2015 inﬂuenza
season), specimens were collected and then stored frozen at 80°C prior to being tested with the Aries
Flu A/B & RSV assay. Most clinical specimens collected during the second phase of the prospective study
(2015 to 2016 inﬂuenza season) were tested by the Aries Flu A/B & RSV assay at the clinical sites after
being kept refrigerated at 4 to 8°C for up to 96 h after collection.
Discordant analysis with bidirectional sequencing. Any discordant specimens where the Aries Flu
A/B & RSV assay results were different from the comparator xTAG RVP assay results were assessed by
bidirectional sequencing using analytically validated primers that were directed against genomic regions
different from those for the Aries Flu A/B & RSV assay. Discordant specimens were subjected to
bidirectional sequencing using M13 forward and reverse primers and the Sanger dideoxy sequencing
method to retrieve DNA sequences. Following extraction by the bioMérieux NucliSENS easyMAG
extraction method, specimens were subjected to RT-PCR using the OneStep Qiagen reverse transcriptase
PCR kit (Qiagen, Hilden, Germany). Amplicons were then treated with exonuclease I and shrimp alkaline
phosphatase enzymes to remove unincorporated primers and deoxynucleoside triphosphates (dNTPs)
left over from the PCRs. Dye-labeled terminator cycle sequencing reactions were performed using the
BigDye Terminator v3.1 cycle sequencing kit (Thermo Fisher, Waltham, MA). Any unincorporated dye was
removed using the BigDye Xterminator puriﬁcation kit (Thermo Fisher). Sample electrophoresis and
sequencing analysis were performed on the 3730xl analyzer (Thermo Fisher) using the 3730xl data
collection software (v 3.1.1) and sequencing analysis software (v 5.4). Sequences that (i) were at least
200 bases in length, (ii) had a PHRED score greater than or equal to 20 for at least 90% of the bases,
and (iii) contained fewer than 5% ambiguous base calls were considered for further analysis using
BLAST (NCBI). Acceptable matches to BLAST reference sequences were those with greater than 95%
query coverage and identity with an expected value (E value) less than 1030 compared with the
reference sequence.
Data collection and analysis. The performance of the Aries Flu A/B & RSV assay for detecting
inﬂuenza A virus, inﬂuenza B virus, and RSV was compared with that of the xTAG RVP assay. Accuracy
determinations for each viral pathogen were based on the fraction of positive (or negative) results by the
comparator method, which were also positive (or negative) by the Aries Flu A/B & RSV assay. An Aries Flu
A/B & RSV assay result was considered to be a true-positive (TP) or true-negative (TN) result if it agreed
with the comparator method result for the pathogen in question. The exact (Clopper-Pearson) method
was used to calculate 95% conﬁdence intervals. Estimates of sensitivity (or positive percent agreement
[PPA]), speciﬁcity (or negative percent agreement [NPA]), the positive predictive value (PPV), and the
negative predictive value (NPV) for each pathogen were calculated based on two-by-two tables (refer-
ence method result versus result from Aries Flu A/B & RSV) for the entire prospective data set.
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